Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding.
about
Adhesive Pili in UTI Pathogenesis and Drug DevelopmentAnatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial InfectionEscherichia coli physiology and metabolism dictates adaptation to diverse host microenvironmentsAdhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 piliStructure-Based Drug Design and Optimization of Mannoside Bacterial FimH AntagonistsEarly severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infectionDistinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesisEvolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.Sensing and adhesion are adaptive functions in the plant pathogenic xanthomonads.Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.Aberrant community architecture and attenuated persistence of uropathogenic Escherichia coli in the absence of individual IHF subunits.Point mutations in FimH adhesin of Crohn's disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response.Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice.Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection.Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection.Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coliUrinary tract infection drives genome instability in uropathogenic Escherichia coli and necessitates translesion synthesis DNA polymerase IV for virulenceHuman Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.Surface Plasmon Resonance (SPR) for the Evaluation of Shear-Force-Dependent Bacterial Adhesion.Microevolution in fimH gene of mucosa-associated Escherichia coli strains isolated from pediatric patients with inflammatory bowel diseaseMetabolism and Fitness of Urinary Tract Pathogens.A set of powerful negative selection systems for unmodified Enterobacteriaceae.Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosidesCombinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.Structure, Function, and Assembly of Adhesive Organelles by Uropathogenic BacteriaThe ST131 Escherichia coli H22 subclone from human intestinal microbiota: Comparison of genomic and phenotypic traits with those of the globally successful H30 subcloneEscherichia coli-mediated impairment of ureteric contractility is uropathogenic E. coli specific.Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli.Application and Optimization of relE as a Negative Selection Marker for Making Definitive Genetic Constructs in Uropathogenic Escherichia coliA central metabolic circuit controlled by QseC in pathogenic Escherichia coli.Comprehensive mutagenesis of the fimS promoter regulatory switch reveals novel regulation of type 1 pili in uropathogenic Escherichia coli.A tale of two pili: assembly and function of pili in bacteria.Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.Androgens Enhance Male Urinary Tract Infection Severity in a New ModelDrug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.Treatment and prevention of urinary tract infection with orally active FimH inhibitors.Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infectionUropathogenic Escherichia coli strain CFT073 disrupts NLRP3 inflammasome activation.
P2860
Q26752944-68D00189-4AEF-47E6-A5E2-B690E3C420ABQ26782602-40F9DEB3-BD4F-4EEB-8394-B05FACD9B2FCQ26859181-1168811C-1C11-4BFB-87E7-3213B2049214Q27321012-6D07B964-37AE-4EC4-B94C-F4C20355E388Q27661999-F1933A1C-101E-4F83-8C88-63886A16C7F3Q28475353-E2C93356-ED99-4403-94DA-230C651D1864Q30408643-172DF51C-F02E-4D41-B193-9B85BAA3422BQ30838228-94FB10A2-E8AB-4BD7-9CED-1F17618CA152Q33843907-1C985E04-59C1-436E-B3F9-6EBD3653CFC6Q34440901-E666CAC1-4052-413D-8BB6-BEEDF75A2F02Q34469467-6A05ACA4-BBC2-408E-A620-752A0B6C54BBQ34565942-03CE418E-B820-45B0-B9B3-8BC0F524A3A4Q34876077-57DD069C-1855-4F8A-B66B-3B3E23D1DDD5Q34876396-32DC4CF9-0DAC-4E41-9DEC-58A7DCD92A8CQ35273075-B5730962-EF09-45B0-80D6-3C9811ADD12DQ35606583-7984C81B-C7EF-4F57-9314-E3D97887A38FQ35693750-23A99D33-FCA9-4FE0-B539-65E14DF961A0Q35809371-B0CC8DAA-8C25-4F4B-865D-EA3C1780B63EQ35824573-DC57F730-46C1-4BAE-A121-E4A984F589A5Q35867599-8747A1D7-691F-4836-9816-7FF46A1A4985Q35877198-E5750560-8FF4-4478-B9AD-7565F8027C9EQ35885858-2539A5E6-20E7-4BD8-9BD9-C5649FC99AB9Q36032748-27A2243F-9433-46D1-A97E-642314094838Q36172411-00975738-5638-452F-A754-FD78D79F6DBFQ36211104-06E29EF0-A625-4485-BB88-0F947AA37002Q36263415-583ADAF7-8C9E-4923-90C4-3A8E30990D8EQ36324271-8FAD288C-0E59-456F-AF6C-D10378B2C69CQ36330963-AAD512C7-C04C-4D0C-9E61-AD01A42DCFD5Q36396848-A4F23E8B-EB21-4042-B276-3DFC73FFDDC9Q36735402-D92D77F8-5C7F-418B-B8AE-A1AF40FF3CBBQ36814083-95AAD16A-9792-48AF-B1F4-B3AFC3374D8AQ36821441-37280E65-BE6B-4C95-B45C-6144C9AB90CCQ36908459-B4562435-F3B5-4AE8-8D93-1FABC3295249Q36910650-FF1ACB77-5E6A-4C45-A0C4-DC1A7957E3FCQ36933039-896948B9-D608-4FB3-9EEB-7336F35DAC6BQ36944667-421DC085-CE30-4FCE-897D-DF9C98D6B8A3Q36951570-A06BB555-D4B1-43C3-A373-759489106892Q36961034-3B7A54C0-CFEB-44CF-AD76-187B5DA7DE0FQ36964199-E888A8D5-A66B-4E10-B1A0-79E26CFBF232Q37042305-3BBF1CC0-DD5F-4CEA-BE94-10D5B43A8970
P2860
Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Positive selection identifies ...... n addition to mannose binding.
@en
Positive selection identifies ...... n addition to mannose binding.
@nl
type
label
Positive selection identifies ...... n addition to mannose binding.
@en
Positive selection identifies ...... n addition to mannose binding.
@nl
prefLabel
Positive selection identifies ...... n addition to mannose binding.
@en
Positive selection identifies ...... n addition to mannose binding.
@nl
P2093
P2860
P356
P1476
Positive selection identifies ...... in addition to mannose binding
@en
P2093
Chia S Hung
Corinne K Cusumano
Jennifer N Walker
Jerome S Pinkner
Julie Bouckaert
Scott J Hultgren
P2860
P304
22439-22444
P356
10.1073/PNAS.0902179106
P407
P577
2009-12-16T00:00:00Z